SeaStar Medical Holding Corp (ICUCW) shareholders
ICUCWNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as ICU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 3/309% above fair value
$0.01−0.01 (-34.73%)
Close on Oct 30, 2026Market cap $9.87MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1M
Shares held, 13F filers
Institutional holders
14
4 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $8.54K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daniel B. Asher Joint filing with Mitchell P. Kopin (9.99%), Intracoastal Capital LLC (9.99%) | 3,980,665 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 1,019,958 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Intracoastal Capital LLC Joint filing with Mitchell P. Kopin (9.99%), Daniel B. Asher (9.99%) | 443,253 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Ayrton Capital LLC Joint filing with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (6.52%), Waqas Khatri (6.52%) | 278,436 | 6.52% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ICUCW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Boothbay Fund Management, LLC | 245,200 | – | $899.88K | – | 0.01% |
| Linden Advisors LP | 218,073 | – | $3.51K | – | 0.00% |
| Goldman Sachs Group Inc | 211,381 | – | $3.66K | – | 0.00% |
| LMR Partners LLP | 125,000 | – | $2.16K | – | 0.00% |
| Clear Street Group Inc. | 46,690 | – | $808 | +200 | 0.00% |
| Virtu Financial LLC | 40,316 | – | $1.00K | New | 0.00% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 40,000 | – | $692 | – | 0.00% |
| Susquehanna International Group, Llp | 36,179 | – | $539 | New | 0.00% |
| Equitec Proprietary Markets, LLC | 35,700 | – | $618 | – | 0.00% |
| Cruiser Capital Advisors, LLC | 32,473 | – | $562 | – | 0.00% |
| Two Sigma Securities, LLC | 24,322 | – | $421 | New | 0.00% |
| StoneX Group Inc. | 11,086 | – | $208 | New | 0.00% |
| Wolverine Asset Management LLC | 11,081 | – | $192 | −1,200 | 0.00% |
| UBS Group AG | 801 | – | $14 | +84 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 14 | 1M | 4 / 2 | 1 / 0 | 0M | 0M |
| Q1 2026 | 10 | 1M | 1 / 0 | 1 / 5 | 0M | 0M |
| Q4 2025 | 14 | 1M | 2 / 12 | 0 / 2 | 1M | 0M |
| Q3 2025 | 15 | 0M | 3 / 0 | 4 / 0 | 0M | 0M |
| Q2 2025 | 13 | 0M | 1 / 0 | 1 / 1 | 0M | 0M |
| Q1 2025 | 13 | 0M | 1 / 0 | 1 / 1 | 0M | 0M |
| Q4 2024 | 13 | 0M | 2 / 1 | 3 / 3 | 0M | 0M |
| Q3 2024 | 14 | 0M | 2 / 0 | 3 / 4 | 0M | 0M |
| Q2 2024 | 16 | 0M | 2 / 14 | 0 / 5 | 0M | 0M |
| Q1 2024 | 19 | 0M | 0 / 4 | 5 / 7 | 0M | 0M |
| Q4 2023 | 26 | 0M | 1 / 0 | 7 / 4 | 0M | 0M |
| Q3 2023 | 30 | 0M | 4 / 0 | 3 / 3 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Michael Messinger | Chief Financial Officer | 2,500 | Aug 19, 2026 |
| Kevin Chung | Chief Medical Officer | 28,021 | Jul 2, 2026 |
| Eric Schlorff | Chief Executive Officer | 50,140 | Jul 2, 2026 |
| Bradford K. Towne | Principal Accounting Officer | 9,050 | Feb 10, 2026 |
| David A. Green | Chief Financial Officer | 10,323 | Apr 3, 2025 |
| Jennifer A. Baird | Director | 10,620 | Jul 2, 2026 |
| Bernadette N. Vincent | Director | 8,200 | Jul 2, 2026 |
| Heel Kenneth Van | Director | 11,940 | Jul 2, 2026 |
| John Neuman | Director | 16,200 | Jul 2, 2026 |
| Allan Collins | Director | 54,343 | Nov 15, 2024 |
| Rick Barnett | Director | 86,664 | Nov 15, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Messinger Chief Financial Officer | Aug 18, 2026 | Buy | +750 | $3.27 | $2.45K | 2,500 |
| John Neuman Director | Jul 1, 2026 | Award | +4,000 | – | – | 16,200 |
| Jennifer A. Baird Director | Jul 1, 2026 | Award | +4,000 | – | – | 10,620 |
| Eric Schlorff Chief Executive Officer | Jul 1, 2026 | Award | +10,288 | – | – | 50,140 |
| Heel Kenneth Van Director | Jul 1, 2026 | Award | +4,000 | – | – | 11,940 |
| Bernadette N. Vincent Director | Jul 1, 2026 | Award | +4,000 | – | – | 8,200 |
| Kevin Chung Chief Medical Officer | Jul 1, 2026 | Award | +7,202 | – | – | 28,021 |
| Jennifer A. Baird Director | Feb 6, 2026 | Award | +3,000 | – | – | 6,620 |
| Eric Schlorff Chief Executive Officer | Feb 6, 2026 | Award | +30,000 | – | – | 39,852 |
| Bradford K. Towne Principal Accounting Officer | Feb 6, 2026 | Award | +7,500 | – | – | 9,050 |
| Kevin Chung Chief Medical Officer | Feb 6, 2026 | Award | +15,000 | – | – | 20,819 |
| John Neuman Director | Feb 6, 2026 | Award | +3,000 | – | – | 12,200 |
| Bernadette N. Vincent Director | Feb 6, 2026 | Award | +3,000 | – | – | 4,200 |
| Heel Kenneth Van Director | Feb 6, 2026 | Award | +3,000 | – | – | 7,940 |
| Jennifer A. Baird Director | Dec 19, 2025 | Buy | +4,200 | $0.24 | $1.01K | 36,200 |
| Michael Messinger Chief Financial Officer | Dec 9, 2025 | Buy | +14,500 | $0.35 | $5.08K | 17,500 |
| Heel Kenneth Van Director | Aug 27, 2025 | Buy | +10,000 | $0.86 | $8.60K | 49,400 |
| Heel Kenneth Van Director | Aug 26, 2025 | Buy | +25,000 | $0.89 | $22.25K | 39,400 |
| Kevin Chung Chief Medical Officer | Aug 22, 2025 | Buy | +10,000 | $0.80 | $8.00K | 58,184 |
| Bernadette N. Vincent Director | Jul 10, 2025 | Award | +4,000 | – | – | 12,000 |
| Heel Kenneth Van Director | Jul 10, 2025 | Award | +4,000 | – | – | 14,400 |
| John Neuman Director | Jul 10, 2025 | Award | +4,000 | – | – | 92,000 |
| Jennifer A. Baird Director | Jul 10, 2025 | Award | +4,000 | – | – | 32,000 |
| Eric Schlorff Chief Executive Officer, Director | Jul 1, 2025 | Option exercise | +21,667 | – | – | 98,517 |
| Kevin Chung Chief Medical Officer | Jul 1, 2025 | Option exercise | +5,000 | – | – | 48,184 |
| Jennifer A. Baird Director | Jun 30, 2025 | Buy | +10,000 | $0.42 | $4.20K | 28,000 |
| John Neuman Director | Jun 24, 2025 | Buy | +40,000 | $0.36 | $14.40K | 80,000 |
| Bernadette N. Vincent Director | Jun 4, 2025 | Option exercise | +2,667 | – | – | 8,000 |
| Heel Kenneth Van Director | Jun 4, 2025 | Option exercise | +4,000 | – | – | 10,400 |
| John Neuman Director | Jun 4, 2025 | Option exercise | +2,667 | – | – | 88,000 |
| Jennifer A. Baird Director | Jun 4, 2025 | Option exercise | +2,667 | – | – | 18,000 |
| Jennifer A. Baird Director | May 20, 2025 | Buy | +10,000 | $1.28 | $12.80K | 10,000 |
| Kevin Chung Chief Medical Officer | May 20, 2025 | Buy | +4,500 | $1.25 | $5.63K | 18,185 |
| John Neuman Director | Dec 11, 2024 | Buy | +10,000 | $2.04 | $20.40K | 40,000 |
| Kevin Chung Chief Medical Officer | Nov 18, 2024 | Buy | +4,250 | $1.99 | $8.46K | 13,685 |
| Kevin Chung Chief Medical Officer | Sep 30, 2024 | Buy | +1,000 | $4.26 | $4.26K | 9,435 |
| David A. Green Chief Financial Officer | Aug 30, 2024 | Award | +8,100 | – | – | 10,323 |
| John Neuman Director | Aug 15, 2024 | Buy | +10,000 | $5.24 | $52.40K | 30,000 |
| John Neuman Director | Jun 17, 2024 | Buy | +10,000 | $4.35 | $43.50K | 20,000 |
| John Neuman Director | Jun 14, 2024 | Buy | +10,000 | $3.69 | $36.90K | 10,000 |
| David A. Green Chief Financial Officer | Apr 18, 2024 | Award | +2,223 | – | – | 2,223 |
| Allan Collins Director | Apr 12, 2024 | Award | +37,943 | – | – | 54,343 |
| Bruce M. Rodgers Director | Apr 12, 2024 | Award | +36,537 | – | – | 44,515 |
| Heel Kenneth Van Director | Apr 12, 2024 | Award | +43,564 | – | – | 159,964 |
| Andres Lobo Director | Apr 12, 2024 | Award | +32,322 | – | – | 40,300 |
| Rick Barnett Director | Apr 12, 2024 | Award | +70,264 | – | – | 86,664 |
| David A. Green Chief Financial Officer | Apr 12, 2024 | Award | +752,500 | – | – | 752,500 |
| Richard D. Russell Director | Apr 12, 2024 | Award | +32,322 | – | – | 60,300 |
| Kevin Chung Chief Medical Officer | Nov 29, 2023 | Award | +63,422 | – | – | 210,860 |
| Eric Schlorff Chief Executive Officer, Director | Nov 29, 2023 | Award | +60,248 | – | – | 837,823 |
| Caryl Baron Interim CFO | Nov 29, 2023 | Award | +20,293 | – | – | 139,872 |
| Heel Kenneth Van Director | Nov 22, 2023 | Buy | +100,000 | $0.40 | $40.00K | 116,400 |
| Caryl Baron Interim CFO | Sep 22, 2023 | Other | +15,070 | – | – | 119,579 |
| Caryl Baron Interim CFO | Sep 15, 2023 | Award | +4,110 | – | – | 104,506 |
| Eric Schlorff Chief Executive Officer, Director | Sep 15, 2023 | Award | +41,109 | – | – | 779,862 |
| Kevin Chung Chief Medical Officer | Sep 15, 2023 | Award | +34,257 | – | – | 154,490 |
| Kevin Chung Chief Medical Officer | Aug 31, 2023 | Award | +28,125 | – | – | 113,181 |
| Eric Schlorff Chief Executive Officer, Director | Aug 31, 2023 | Award | +33,750 | – | – | 736,466 |
| Kevin Chung Chief Medical Officer | Aug 31, 2023 | Award | +35,178 | – | – | 120,233 |
| Eric Schlorff Chief Executive Officer, Director | Aug 31, 2023 | Award | +35,178 | – | – | 738,753 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-50.7%
From 0M shares
Short volume, 20 days
50.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of SeaStar Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 977 shares on Aug 6, 2026 over the last 90 days.